ALX Oncology Appoints New Chairman and General Counsel Following Co-Founder's Resignation
ALXO has more than doubled off its 52-week low of $0.41.
Summary
ALX Oncology announced leadership changes, including the resignation of co-founder Chairman Corey Goodman and the appointment of Scott Garland as his successor, alongside a new General Counsel.
Key Events · Executive and Board Changes · ALXO
-
Co-Founder Chairman Resigns
Corey Goodman, Ph.D., co-founder and Chairman of the Board, resigned for personal reasons, effective June 29, 2026. The company stated there were no disagreements regarding operations, policies, or practices.
-
New Chairman Appointed
Scott Garland, an independent director since November 2022, was appointed as the new Chairman of the Board, effective June 29, 2026, providing leadership continuity.
-
New General Counsel Appointed
Michael Listgarten was appointed as General Counsel, bringing over 30 years of legal and biopharmaceutical industry experience, particularly in guiding companies through late-stage clinical development to commercialization.
-
Board Committee Recomposition
The Audit, Compensation, and Corporate Governance and Nominating Committees were updated following the board changes, with Scott Garland joining the Audit and Compensation Committees.
Analysis · ALXO · Life Sciences
Corey Goodman, a co-founder and Chairman of the Board, resigned for personal reasons, with no reported disagreements. The board promptly appointed existing independent director Scott Garland as the new Chairman, ensuring leadership continuity. Additionally, the company appointed Michael Listgarten as General Counsel, bringing over 30 years of legal and biopharmaceutical experience to the executive team as ALX Oncology advances its clinical programs.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.5% of the 1626 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALXO was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $277.9M. The 52-week trading range was $0.41 to $2.66. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.